Aditxt, Inc. Common Stock
ADTXAditxt, Inc. (ADTX) is a biotechnology company focused on developing solutions to monitor, improve, and extend the health of the immune system. The company leverages its proprietary AditxtScore platform to assess immune system health and has interests in vaccine development and immunology research. Aditxt aims to address immune-related health issues through innovative technologies and therapies.
Company News
U.S. stock futures rose on Wednesday after a mixed market close, with uncertainty surrounding November's jobs report and potential Federal Reserve interest rate decisions. Key companies reported earnings with varied results.
Women's health company Evofem Biosciences reported increased net sales of $5.0 million in Q3 2025, a 10% increase from the previous year. The company achieved $1.0 million in operating income, reduced operating expenses by 42%, and advanced strategies to lower manufacturing costs for its products PHEXX and SOLOSEC.
Evofem Biosciences shareholders rejected a proposed merger with Aditxt, leading the company to terminate the merger agreement and pivot towards regaining a national stock listing and securing growth capital.
Evofem Biosciences launched a provocative "Say Vagina" campaign in August 2025, generating over 2.5 million social media views and increasing website traffic by 130%, aimed at normalizing medical terminology and women's health discussions.
Evofem Biosciences plans to merge with Aditxt, with a stockholder meeting scheduled for September 26, 2025. The company believes it has sufficient voting support to approve the merger, which would position Evofem as a subsidiary of Aditxt focused on women's healthcare innovations.
